358 related articles for article (PubMed ID: 16797726)
1. Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences.
Sibéril S; Dutertre CA; Boix C; Bonnin E; Ménez R; Stura E; Jorieux S; Fridman WH; Teillaud JL
Immunol Lett; 2006 Aug; 106(2):111-8. PubMed ID: 16797726
[TBL] [Abstract][Full Text] [Related]
2. FcgammaR: The key to optimize therapeutic antibodies?
Sibéril S; Dutertre CA; Fridman WH; Teillaud JL
Crit Rev Oncol Hematol; 2007 Apr; 62(1):26-33. PubMed ID: 17240158
[TBL] [Abstract][Full Text] [Related]
3. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
4. Design and expression of polymeric immunoglobulin fusion proteins: a strategy for targeting low-affinity Fcgamma receptors.
White DM; Jensen MA; Shi X; Qu Zx ; Arnason BG
Protein Expr Purif; 2001 Apr; 21(3):446-55. PubMed ID: 11281720
[TBL] [Abstract][Full Text] [Related]
5. The localization of the binding site(s) on human IgG1 for the Fc receptors on homologous monocytes and heterologous mouse macrophages.
Ratcliffe A; Stanworth DR
Immunology; 1983 Sep; 50(1):93-100. PubMed ID: 6885113
[TBL] [Abstract][Full Text] [Related]
6. When binding is enough: nonactivating antibody formats.
Labrijn AF; Aalberse RC; Schuurman J
Curr Opin Immunol; 2008 Aug; 20(4):479-85. PubMed ID: 18577454
[TBL] [Abstract][Full Text] [Related]
7. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
8. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
Pollastrini J; Dillon TM; Bondarenko P; Chou RY
Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
[TBL] [Abstract][Full Text] [Related]
9. Isotype and glycoform selection for antibody therapeutics.
Jefferis R
Arch Biochem Biophys; 2012 Oct; 526(2):159-66. PubMed ID: 22465822
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
11. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
12. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface.
Teplyakov A; Zhao Y; Malia TJ; Obmolova G; Gilliland GL
Mol Immunol; 2013 Nov; 56(1-2):131-9. PubMed ID: 23628091
[TBL] [Abstract][Full Text] [Related]
13. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
14. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
15. [A stable conformer of IgG, prepared by an acidic influence: study by calorimetry, binding of the C1q complement component, and monospecific anti-IgG].
Kravchuk ZI; Vlasov AP; Liakhnovich GV; Martsev SP
Biokhimiia; 1994 Oct; 59(10):1458-77. PubMed ID: 7819387
[TBL] [Abstract][Full Text] [Related]
16. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
17. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
Newman R; Hariharan K; Reff M; Anderson DR; Braslawsky G; Santoro D; Hanna N; Bugelski PJ; Brigham-Burke M; Crysler C; Gagnon RC; Dal Monte P; Doyle ML; Hensley PC; Reddy MP; Sweet RW; Truneh A
Clin Immunol; 2001 Feb; 98(2):164-74. PubMed ID: 11161972
[TBL] [Abstract][Full Text] [Related]
18. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.
Vaccaro C; Zhou J; Ober RJ; Ward ES
Nat Biotechnol; 2005 Oct; 23(10):1283-8. PubMed ID: 16186811
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.
Caaveiro JM; Kiyoshi M; Tsumoto K
Immunol Rev; 2015 Nov; 268(1):201-21. PubMed ID: 26497522
[TBL] [Abstract][Full Text] [Related]
20. Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function.
Isaacs JD; Greenwood J; Waldmann H
J Immunol; 1998 Oct; 161(8):3862-9. PubMed ID: 9780151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
